CARLA SCHLENKE: Open Payments
NPI 1720101892 · ORANGE PARK, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,081 in 48 payments from 15 companies in 2025. Trend: 2023 $509 · 2024 $549 · 2025 $1,081
Food & beverage: $1,081
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $222 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $187 |
| Lundbeck LLC | 5 | $141 |
| Alkermes, Inc. | 4 | $104 |
| Axsome Therapeutics, Inc. | 4 | $101 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Almatica Pharma LLC | 1 | $29 |
| Neurocrine BioSciences, Inc. | 1 | $27 |
Products named: VRAYLAR, CAPLYTA, REXULTI, ARISTADA, Auvelity, AUSTEDO XR, COBENFY, FANAPT.
Industry payments across FL — which companies pay providers there.
